<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33436881</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS.</ArticleTitle><Pagination><StartPage>703</StartPage><MedlinePgn>703</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">703</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-80370-6</ELocationID><Abstract><AbstractText>This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF. Candidate markers levels were measured using multiplex method in serum of 60 ALS patients, 94 healthy controls of 43 patients suffering from Inflammatory Peripheral Neuropathies (IPN). A comparative CSF analysis was performed for 20 ALS and 17 IPN patients. Among the altered biomarkers, CSF Nf-L level remains the best marker of ALS severity, while serum levels correlate strongly with disease progression. The combination of Nf-L and ICAM-1 concentrations in the CSF and IFN-&#x3b3; concentration in the serum differentiate ALS patients from IPN patients with improved sensibility and specificity relative to individual biomarkers. A cutoff value of 0.49 for the fitted values of these 3 biomarkers discriminate ALS from IPN patients with a specificity of 100% (78.20-100%) and a sensibility of 85.71% (57.19-98.22%) with an AUC of 0.99&#x2009;&#xb1;&#x2009;0.01. The measure of Nf-L and neuroinflammatory biomarkers in CSF and serum can be useful biomarkers panel in the differential diagnosis of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brodovitch</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Timone Hospital, Referral Centre for Neuromuscular Diseases and ALS, AP-HM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Laboratory, Conception Hospital, AP-HM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boucraut</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Immunology Laboratory, Conception Hospital, AP-HM, Marseille, France. jose.boucraut@univ-amu.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INT UMR CNRS 7289, Medicine Faculty, Aix Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille Cedex 05, France. jose.boucraut@univ-amu.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmont</LastName><ForeName>Emilien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Timone Hospital, Referral Centre for Neuromuscular Diseases and ALS, AP-HM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INT UMR CNRS 7289, Medicine Faculty, Aix Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille Cedex 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parlanti</LastName><ForeName>Amandine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Timone Hospital, Referral Centre for Neuromuscular Diseases and ALS, AP-HM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grapperon</LastName><ForeName>Aude-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Timone Hospital, Referral Centre for Neuromuscular Diseases and ALS, AP-HM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CRMBM UMR CNRS 7339, Aix Marseille University, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attarian</LastName><ForeName>Shahram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Timone Hospital, Referral Centre for Neuromuscular Diseases and ALS, AP-HM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM UMR S910, GMGF, Aix Marseille University, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verschueren</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Timone Hospital, Referral Centre for Neuromuscular Diseases and ALS, AP-HM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CRMBM UMR CNRS 7339, Aix Marseille University, Marseille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573420">ICAM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>126547-89-5</RegistryNumber><NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33436881</ArticleId><ArticleId IdType="pmc">PMC7803734</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-80370-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-80370-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Traynor BJ, et al. Amyotrophic lateral sclerosis mimic syndromes: A population-based study. Arch. Neurol. 2000;57:109&#x2013;113. doi: 10.1001/archneur.57.1.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.1.109</ArticleId><ArticleId IdType="pubmed">10634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser J, et al. Mimic syndromes in sporadic cases of progressive spinal muscular atrophy. Neurology. 2002;58:1593&#x2013;1596. doi: 10.1212/WNL.58.11.1593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.11.1593</ArticleId><ArticleId IdType="pubmed">12058084</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2013;revised report of an EFNS task force. Eur. J. Neurol. 2012;19:360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu LT, Bowser R. Fluid-based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14:119&#x2013;134. doi: 10.1007/s13311-016-0503-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0503-x</ArticleId><ArticleId IdType="pmc">PMC5233638</ArticleId><ArticleId IdType="pubmed">27933485</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry. 2016;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: A systematic review and meta-analysis. PLoS ONE. 2016;11:e0164625. doi: 10.1371/journal.pone.0164625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164625</ArticleId><ArticleId IdType="pmc">PMC5061412</ArticleId><ArticleId IdType="pubmed">27732645</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D, et al. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J. Neurol. 2018;265:510&#x2013;521. doi: 10.1007/s00415-017-8730-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotto S, et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J. Peripher. Nerv. Syst. 2018;23:174&#x2013;177. doi: 10.1111/jns.12279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12279</ArticleId><ArticleId IdType="pubmed">29974556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 2019 doi: 10.1001/jamaneurol.2019.3238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3238</ArticleId><ArticleId IdType="pmc">PMC6745051</ArticleId><ArticleId IdType="pubmed">31515562</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat. Med. 2019;25:277&#x2013;283. doi: 10.1038/s41591-018-0304-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int. Immunol. 2015;27:117&#x2013;129. doi: 10.1093/intimm/dxu099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxu099</ArticleId><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:364&#x2013;375. doi: 10.1007/s13311-014-0329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci. Rep. 2017;7:9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Alirezaei Z, et al. Neurofilament light chain as a biomarker, and correlation with magnetic resonance imaging in diagnosis of CNS-related disorders. Mol. Neurobiol. 2020;57:469&#x2013;491. doi: 10.1007/s12035-019-01698-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-01698-3</ArticleId><ArticleId IdType="pmc">PMC6980520</ArticleId><ArticleId IdType="pubmed">31385229</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, et al. Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc. Natl. Acad. Sci. USA. 2019;116:2312&#x2013;2317. doi: 10.1073/pnas.1815961116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815961116</ArticleId><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 2017;7:e00637. doi: 10.1002/brb3.637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.637</ArticleId><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainaghi PP, et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain&#x2013;Barr&#xe9; syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine. 2010;51:138&#x2013;143. doi: 10.1016/j.cyto.2010.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2010.05.005</ArticleId><ArticleId IdType="pubmed">20538476</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Michalopoulou M, Nikolaou C, Rombos A, Dimitrakopoulos A. Serum levels of soluble intercellular adhesion molecule-1 (s-ICAM-1) and soluble endothelial leukocyte adhesion molecule-1(s-ELAM-1) in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2005;6:118&#x2013;121. doi: 10.1080/14660820410021311a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410021311a</ArticleId><ArticleId IdType="pubmed">16036437</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MC, Couch Y, Sibson N, Turner MR. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 2013;53:34&#x2013;41. doi: 10.1016/j.mcn.2012.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2012.10.008</ArticleId><ArticleId IdType="pubmed">23110760</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Gao L, Zang D. Elevated levels of IFN-&#x3b3; in CSF and serum of patients with amyotrophic lateral sclerosis. PLoS ONE. 2015;10:e0136937. doi: 10.1371/journal.pone.0136937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136937</ArticleId><ArticleId IdType="pmc">PMC4557946</ArticleId><ArticleId IdType="pubmed">26332465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016;3:e244. doi: 10.1212/NXI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74:1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, B. R., Miller, R. G., Swash, M., Munsat, T. L. &amp; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord.1, 293&#x2013;299 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzeaux R, et al. How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays. Psychoneuroendocrinology. 2017;75:72&#x2013;82. doi: 10.1016/j.psyneuen.2016.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2016.10.010</ArticleId><ArticleId IdType="pubmed">27810706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>